A Phase 3 interventional study of dimethyl fumarate in Multiple Sclerosis, Relapsing-Remitting and Multiple Sclerosis, sponsored by Biogen. Completed at 34 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-06-27.
Sponsored by Biogen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting — none open to participants now, none under way, none of them phase 3. Dimethyl Fumarate · Multiple Sclerosis, Relapsing-Remitting.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, this one is the 7th largest by enrollment, is one of 6 that started in 2015, is one of 10 in phase 3, and was the 16th registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →None of the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting is open now. The open studies under Multiple Sclerosis, Relapsing-Remitting, anywhere →
Dimethyl Fumarate: first FDA approval 2013 (TECFIDERA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 61 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 44 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 6 started in 2015.
This study's enrollment of 218 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 61 across the 22 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 22 have an industry lead sponsor. The 5 most frequent:
Biogen is the lead sponsor of 512 studies on the registry; 25 are open to participants now.
Of its 100 completed or terminated interventional studies of FDA-regulated products, 50 (50%) have results posted.
78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen: none open now, 1 under way, 1 of them phase 3. Of 72 finished, 31 (43%) have results posted.
Among the 78 studies in Multiple Sclerosis, Relapsing-Remitting by Biogen, this one is the 25th largest by enrollment of the 59 interventional ones that give a count, is one of 8 that started in 2015, is one of 25 in phase 3, and was the 56th registered.
Biogen’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing Dimethyl Fumarate in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Biogen’s 78 in Multiple Sclerosis, Relapsing-Remitting:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of the study is to evaluate the effect of BG00012 on lymphocyte subset counts during the first year of treatment in subjects with relapsing-remitting multiple sclerosis (RRMS). A secondary objective is to evaluate the pharmacodynamic effect on absolute lymphocyte counts (ALCs) and immunoglobulins (Igs) during the first year of treatment.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
120 mg twice daily (BID) for the first 7 days and 240 mg BID thereafter
Drug: dimethyl fumarate
Initial oral dose for 7 days with maintenance dose thereafter
Also known as: BG00012, Tecfidera, DMF
Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T Cell, B Cell, Natural Killer Cell (TBNK)
Lymphocyte subsets include T cell, B cell and Natural killer (NK) cells.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T-Cells Subsets
T-cells subsets includes Activated CD4+ T-cell, Activated CD8+ T-cell, Activated CD8+ T-cell \[CD38+\], Activated Th (T helper) 1 phenotype, Activated Th17 phenotype, Activated Th2-enriched phenotype, Activated CD4+ T-cell \[CD38+HLA-DR+\], Activated CD4+ T-cell \[HLA-DR+\], Activated CD8+ T-cell \[HLA-DR+\], Central Memory (CM) CD4+ T-cell \[CD45RA-CCR7+\], CM CD4+ T-cell \[CD45RA-CCR7+\], CM CD8+ T-cell \[CD45RA-CCR7+\], Effector CD4+ T-cell \[CD45RA+CCR7-\], Effector CD8+ T-cell \[CD45RA+CCR7-\], Effector Memory (EM) CD4+ T-cell \[CD45RA-CCR7-\], EM CD8+ T-cell \[CD45RA-CCR7-\], Effector Regulatory T-cells, Effector CD4+ T-cell \[CD45RA+CCR7-\], Effector CD8+ T-cell \[CD45RA+CCR7-\], Naïve CD4+ T-cell \[CD45RA+\], Naïve CD8+ T-cell \[CD45RA+\], Naïve (N) CD8+ T-cell \[CD45RA+\], Naïve Regulatory T-cells, Terminal Effector Regulatory T-cells, Th1 phenotype, Th17 phenotype, Th2-enriched phenotype. Here, Change at week is represented as CW.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: B-Cell Subsets
B-cell subsets include CD10+ Transitional B cells, CD138+ Plasma Cells, Ig (Immunoglobulin) D+ Memory B cells \[non-class switched\], IgD- Memory B cells \[class switched\], Naïve B cells, Plasma Cells \[CD10-\], Transitional B-cells and Plasmablasts. Here, Change at week is represented as CW.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: Myeloid and Natural Killer (NK) Cells
Myeloid and natural killer cell subsets include CD56Bright NK cells, CD56Dim NK cells, Classical Monocytes, Myeloid dendritic cells, Non-classical Monocytes, Plasmacytoid dendritic cells, Total dendritic cells and Total monocytes \[CD14+\].
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: T-Cell Cytokines
T-cell cytokine subsets include IFN (interferon) g+ (% of CD4+ T cells), IFNg+ (% of CD8+ T cells), IFNg+ (% of memory CD4+ T cells), IFNg+ (% of memory CD8+ T cells), IL- (interleukin) 17A+/IFNg- (% of CD4+ T cells), IL-17A+/IFNg- (% of CD8+ T cells), IL-17A+/IFNg- (% of memory CD4+ T cells), IL-17A+/IFNg- (% of memory CD8+ T cells), IL-2+ (% of CD4+ T cells), IL-2+ (% of CD8+ T cells), IL-2+ (% of memory CD4+ T cells), IL-2+ (% of memory CD8+ T cells), IL-4+ (% of CD4+ T cells), IL-4+ (% of CD8+ T cells), IL-4+ (% of memory CD4+ T cells) and IL-4+ (% of memory CD8+ T cells). Here, Change at week is represented as CW.
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Lymphocyte Subsets Counts up to 48 Weeks: Very Late Antigen-4 (VLA-4/Lymphocyte Function-Associated Antigen-1 (LFA-1) Antigen
VLA-4/LFA-1 antigen subsets include CD11a+ (% of B cells), CD11a+ (% of T cells), CD11a+ (% of MNC), CD11a+ (% of dendritic cells \[CD11c++\]), CD11a+ (% of lymphocytes), CD11a+ (% of monocytes), CD11a+ (% of neutrophils), CD49d+ (% of B cells), CD49d+ (% of T cells), CD49d+ (% of MNC), CD49d+ (% of dendritic cells \[CD11c++\]), CD49d+ (% of lymphocytes), CD49d+ (% of monocytes) and CD49d+ (% of neutrophils).
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Immunoglobulin A (IgA) up to 48 Weeks
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Immunoglobulin M (IgM) up to 48 Weeks
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Immunoglobulin G (IgG) up to 48 Weeks
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
Change From Baseline in Immunoglobulin G (IgG) Subclasses up to 48 Weeks
Time frame: Baseline, Week 4, Week 8, Week 12, Week 24, Week 36 and Week 48
This study was conducted from 11 August 2015 to 23 April 2018 in Belgium, Bulgaria, Lithuania, Kuwait, Poland and United States.
| Milestone | Dimethyl Fumarate (BG00012) |
|---|---|
| Started | 218 |
| Completed | 158 |
| Not completed | 60 |
| Withdrew: Other | 1 |
| Withdrew: Investigator decision | 1 |
| Withdrew: Consent withdrawn | 22 |
| Withdrew: Non-compliance with study drug | 3 |
| Withdrew: Adverse event | 17 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Disease progression, defined by protocol | 2 |
| Withdrew: Disease relapse | 4 |
| Withdrew: Alternative treatment for ms | 2 |
| Withdrew: New lesions in brain | 1 |
Lymphocyte subsets include T cell, B cell and Natural killer (NK) cells.
| cells per cubic millimeter (cells/mm^3) | Dimethyl Fumarate (BG00012) |
|---|---|
| B Cells: Baseline | 235.9 ± 168.88 |
| B Cells: Change at Week 4 | -18.8 ± 89.71 |
| B Cells: Change at Week 8 | -48.2 ± 122.20 |
| B Cells: Change at Week 12 | -65.9 ± 128.53 |
| B Cells: Change at Week 24 | -76.5 ± 140.33 |
| B Cells: Change at Week 36 | -70.1 ± 104.80 |
| B Cells: Change at Week 48 | -60.7 ± 115.26 |
| NK Cells: Baseline | 184.2 ± 107.12 |
| NK Cells: Change at Week 4 | 6.1 ± 84.66 |
| NK Cells: Change at Week 8 | -9.0 ± 89.55 |
| NK Cells: Change at Week 12 | -21.7 ± 90.82 |
| NK Cells: Change at Week 24 | -26.9 ± 88.06 |
| NK Cells: Change at Week 36 | -41.5 ± 90.37 |
| NK Cells: Change at Week 48 | -42.0 ± 104.88 |
| T Cells: Baseline | 1318.1 ± 544.00 |
| T Cells: Change at Week 4 | -44.8 ± 383.55 |
| T Cells: Change at Week 8 | -167.0 ± 482.86 |
| T Cells: Change at Week 12 | -284.3 ± 527.58 |
| T Cells: Change at Week 24 | -446.7 ± 542.06 |
| T Cells: Change at Week 36 | -545.5 ± 550.87 |
| T Cells: Change at Week 48 | -580.2 ± 551.52 |
| CD4+ T cells: Baseline | 879.0 ± 400.71 |
| CD4+ T cells: Change at Week 4 | -27.4 ± 256.21 |
| CD4+ T cells: Change at Week 8 | -95.4 ± 318.07 |
| CD4+ T cells: Change at Week 12 | -176.8 ± 353.52 |
| CD4+ T cells: Change at Week 24 | -269.8 ± 360.92 |
| CD4+ T cells: Change at Week 36 | -329.7 ± 374.66 |
| CD4+ T cells: Change at Week 48 | -352.6 ± 380.77 |
| CD8+ T cells: Baseline | 419.5 ± 203.76 |
| CD8+ T cells:Change at Week 4 | -14.2 ± 147.21 |
| CD8+ T cells:Change at Week 8 | -65.3 ± 181.65 |
| CD8+ T cells:Change at Week 12 | -100.4 ± 193.28 |
| CD8+ T cells:Change at Week 24 | -170.2 ± 201.14 |
| CD8+ T cells:Change at Week 36 | -201.4 ± 203.10 |
| CD8+ T cells:Change at Week 48 | -214.9 ± 203.62 |
T-cells subsets includes Activated CD4+ T-cell, Activated CD8+ T-cell, Activated CD8+ T-cell \[CD38+\], Activated Th (T helper) 1 phenotype, Activated Th17 phenotype, Activated Th2-enriched phenotype, Activated CD4+ T-cell \[CD38+HLA-DR+\], Activated CD4+ T-cell \[HLA-DR+\], Activated CD8+ T-cell \[HLA-DR+\], Central Memory (CM) CD4+ T-cell \[CD45RA-CCR7+\], CM CD4+ T-cell \[CD45RA-CCR7+\], CM CD8+ T-cell \[CD45RA-CCR7+\], Effector CD4+ T-cell \[CD45RA+CCR7-\], Effector CD8+ T-cell \[CD45RA+CCR7-\], Effector Memory (EM) CD4+ T-cell \[CD45RA-CCR7-\], EM CD8+ T-cell \[CD45RA-CCR7-\], Effector Regulatory T-cells, Effector CD4+ T-cell \[CD45RA+CCR7-\], Effector CD8+ T-cell \[CD45RA+CCR7-\], Naïve CD4+ T-cell \[CD45RA+\], Naïve CD8+ T-cell \[CD45RA+\], Naïve (N) CD8+ T-cell \[CD45RA+\], Naïve Regulatory T-cells, Terminal Effector Regulatory T-cells, Th1 phenotype, Th17 phenotype, Th2-enriched phenotype. Here, Change at week is represented as CW.
| cells/mm^3 | Dimethyl Fumarate (BG00012) |
|---|---|
| Activated CD4+ T-cell [CD38+]: Baseline | 632.6 ± 305.86 |
| Activated CD4+ T-cell [CD38+]: Change at Week 4 | 15.2 ± 241.73 |
| Activated CD4+ T-cell [CD38+]: Change at Week 8 | -26.5 ± 241.47 |
| Activated CD4+ T-cell [CD38+]: Change at Week 12 | -53.4 ± 246.22 |
| Activated CD4+ T-cell [CD38+]: Change at Week 24 | -100.4 ± 263.58 |
| Activated CD4+ T-cell [CD38+]: Change at Week 36 | -106.8 ± 308.03 |
| Activated CD4+ T-cell [CD38+]: Change at Week 48 | -125.9 ± 273.26 |
| Activated CD8+ T-cell ([CD38+HLA-DR+]): Baseline | 22.9 ± 25.64 |
| ActivatedCD8+T-cell(CD38+HLA-DR+):CW 4 | 3.9 ± 21.83 |
| ActivatedCD8+T-cell(CD38+HLA-DR+):CW 8 | -2.2 ± 24.46 |
| ActivatedCD8+T-cell(CD38+HLA-DR+):CW 12 | -3.4 ± 23.53 |
| ActivatedCD8+T-cell(CD38+HLA-DR+):CW 24 | -5.8 ± 24.72 |
| ActivatedCD8+T-cell(CD38+HLA-DR+):CW 36 | -7.9 ± 27.32 |
| ActivatedCD8+T-cell(CD38+HLA-DR+):CW 48 | -7.7 ± 24.92 |
| Activated CD8+ T-cell [CD38+]: Baseline | 275.4 ± 158.04 |
| Activated CD8+ T-cell [CD38+]: Change at Week 4 | 18.2 ± 118.67 |
| Activated CD8+ T-cell [CD38+]: Change at Week 8 | -21.7 ± 126.38 |
| Activated CD8+ T-cell [CD38+]: Change at Week 12 | -50.8 ± 132.08 |
| Activated CD8+ T-cell [CD38+]: Change at Week 24 | -91.8 ± 142.99 |
| Activated CD8+ T-cell [CD38+]: Change at Week 36 | -99.3 ± 162.79 |
| Activated CD8+ T-cell [CD38+]: Change at Week 48 | -114.3 ± 152.39 |
| Activated Th1 phenotype: Baseline | 10.4 ± 6.52 |
| Activated Th1 phenotype: Change at Week 4 | 0.6 ± 6.09 |
| Activated Th1 phenotype: Change at Week 8 | -1.2 ± 6.87 |
| Activated Th1 phenotype: Change at Week 12 | -2.1 ± 6.63 |
| Activated Th1 phenotype: Change at Week 24 | -3.5 ± 6.47 |
| Activated Th1 phenotype: Change at Week 36 | -3.8 ± 6.82 |
| Activated Th1 phenotype: Change at Week 48 | -4.0 ± 6.50 |
| Activated Th17 phenotype: Baseline | 1.1 ± 1.33 |
| Activated Th17 phenotype: Change at Week 4 | 0.0 ± 1.01 |
| Activated Th17 phenotype: Change at Week 8 | -0.2 ± 1.50 |
| Activated Th17 phenotype: Change at Week 12 | 0.0 ± 1.36 |
| Activated Th17 phenotype: Change at Week 24 | -0.4 ± 1.33 |
| Activated Th17 phenotype: Change at Week 36 | -0.4 ± 0.96 |
| Activated Th17 phenotype: Change at Week 48 | -0.3 ± 1.06 |
| Activated Th2-enriched phenotype: Baseline | 4.8 ± 4.83 |
| Activated Th2-enriched phenotype: Change at Week 4 | 1.2 ± 5.36 |
| Activated Th2-enriched phenotype: Change at Week 8 | 0.4 ± 6.13 |
| Activated Th2-enriched phenotype: CW 12 | 0.5 ± 6.54 |
| Activated Th2-enriched phenotype: CW 24 | 0.6 ± 6.84 |
| Activated Th2-enriched phenotype: CW 36 | 0.3 ± 6.57 |
| Activated Th2-enriched phenotype: CW 48 | 0.2 ± 5.14 |
| Activated CD4+ T-cell [CD38+HLA-DR+]: Baseline | 17.3 ± 12.77 |
| ActivatedCD4+ T-cell[CD38+HLA-DR+]:CW 4 | 2.5 ± 11.63 |
| ActivatedCD4+ T-cell[CD38+HLA-DR+]:CW 8 | -0.3 ± 12.81 |
| ActivatedCD4+ T-cell[CD38+HLA-DR+]:CW 12 | -1.6 ± 12.10 |
| ActivatedCD4+ T-cell[CD38+HLA-DR+]:CW 24 | -3.2 ± 13.54 |
| ActivatedCD4+ T-cell[CD38+HLA-DR+]:CW 36 | -4.1 ± 12.07 |
| ActivatedCD4+ T-cell[CD38+HLA-DR+]:CW 48 | -4.2 ± 11.62 |
| Activated CD4+ T-cell [HLA-DR+]: Baseline | 64.6 ± 32.45 |
| Activated CD4+ T-cell [HLA-DR+]: Change at Week 4 | 1.4 ± 27.95 |
| Activated CD4+ T-cell [HLA-DR+]: Change at Week 8 | -5.1 ± 38.57 |
| Activated CD4+ T-cell [HLA-DR+]: Change at Week 12 | -11.7 ± 31.71 |
| Activated CD4+ T-cell [HLA-DR+]: Change at Week 24 | -26.0 ± 30.09 |
| Activated CD4+ T-cell [HLA-DR+]: Change at Week 36 | -33.6 ± 36.39 |
| Activated CD4+ T-cell [HLA-DR+]: Change at Week 48 | -30.1 ± 38.57 |
| Activated CD8+ T-cell [HLA-DR+]: Baseline | 81.2 ± 63.34 |
| Activated CD8+ T-cell [HLA-DR+]: Change at Week 4 | 2.5 ± 46.91 |
| Activated CD8+ T-cell [HLA-DR+]: Change at Week 8 | -5.5 ± 67.56 |
| Activated CD8+ T-cell [HLA-DR+]: Change at Week 12 | -18.2 ± 59.58 |
| Activated CD8+ T-cell [HLA-DR+]: Change at Week 24 | -38.1 ± 57.42 |
| Activated CD8+ T-cell [HLA-DR+]: Change at Week 36 | -48.3 ± 63.85 |
| Activated CD8+ T-cell [HLA-DR+]: Change at Week 48 | -49.3 ± 59.85 |
| CM CD4+ T-cell [CD45RA-CCR7+]: Baseline | 433.4 ± 220.05 |
| CM CD4+ T-cell[CD45RA-CCR7+]:CW 4 | -21.0 ± 185.07 |
| CM CD4+ T-cell[CD45RA-CCR7+]:CW 8 | -68.0 ± 196.02 |
| CM CD4+T-cell[CD45RA-CCR7+]:CW 12 | -105.3 ± 206.11 |
| CM CD4+T-cell[CD45RA-CCR7+]:CW 24 | -204.2 ± 220.61 |
| CentralMemoryCD4+T-cell[CD45RA-CCR7+]:CW 36 | -235.7 ± 221.44 |
| CM CD4+T-cell[CD45RA-CCR7+]:CW 48 | -231.1 ± 225.25 |
| CM CD8+ T-cell [CD45RA-CCR7+]: Baseline | 59.9 ± 60.38 |
| CM CD8+T-cell[CD45RA-CCR7+]:CW 4 | -9.6 ± 45.92 |
| CM CD8+T-cell[CD45RA-CCR7+]:CW 8 | -16.9 ± 41.72 |
| CM CD8+T-cell[CD45RA-CCR7+]:CW 12 | -22.0 ± 48.10 |
| CM CD8+T-cell[CD45RA-CCR7+]:CW 24 | -39.2 ± 50.00 |
| CM CD8+T-cell[CD45RA-CCR7+]:CW 36 | -44.3 ± 55.66 |
| CM CD8+T-cell[CD45RA-CCR7+]:CW 48 | -45.9 ± 53.78 |
| Effector CD4+ T-cell [CD45RA+CCR7-]: Baseline | 12.0 ± 23.21 |
| Effector CD4+ T-cell[CD45RA+CCR7-]:Change atWeek4 | 0.8 ± 12.66 |
| Effector CD4+ T-cell[CD45RA+CCR7-]:Change atWeek8 | -0.1 ± 12.58 |
| Effector CD4+ T-cell[CD45RA+CCR7-]:Change atWeek12 | -1.0 ± 12.43 |
| Effector CD4+ T-cell[CD45RA+CCR7-]:CW 24 | -1.6 ± 17.42 |
| Effector CD4+ T-cell[CD45RA+CCR7-]:CW 36 | -1.9 ± 19.20 |
| Effector CD4+ T-cell[CD45RA+CCR7-]:CW 48 | -4.7 ± 18.75 |
| Effector CD8+ T-cell [CD45RA+CCR7-]: Baseline | 101.4 ± 91.95 |
| Effector CD8+ T-cell[CD45RA+CCR7-]:Change atWeek4 | 1.7 ± 63.49 |
| Effector CD8+ T-cell[CD45RA+CCR7-]:Change atWeek8 | -15.9 ± 67.93 |
| Effector CD8+ T-cell[CD45RA+CCR7-]:CW 12 | -15.2 ± 80.78 |
| Effector CD8+ T-cell[CD45RA+CCR7-]:CW 24 | -42.8 ± 74.14 |
| Effector CD8+ T-cell[CD45RA+CCR7-]:CW 36 | -55.6 ± 78.88 |
| Effector CD8+ T-cell[CD45RA+CCR7-]:CW 48 | -50.9 ± 82.46 |
| EM CD4+ T-cell [CD45RA-CCR7-]: Baseline | 179.7 ± 86.21 |
| EM CD4+ T-cell [CD45RA-CCR7-]: Change at Week 4 | 10.9 ± 87.56 |
| EM CD4+ T-cell [CD45RA-CCR7-]: Change at Week 8 | -33.2 ± 88.53 |
| EM CD4+ T-cell [CD45RA-CCR7-]: Change at Week 12 | -55.2 ± 90.59 |
| EM CD4+ T-cell [CD45RA-CCR7-]: Change at Week 24 | -81.7 ± 106.78 |
| EM CD4+ T-cell [CD45RA-CCR7-]: Change at Week 36 | -98.1 ± 111.77 |
| EM CD4+ T-cell [CD45RA-CCR7-]: Change at Week 48 | -118.5 ± 100.25 |
| EM CD8+ T-cell [CD45RA-CCR7-]: Baseline | 129.0 ± 92.24 |
| EM CD8+ T-cell [CD45RA-CCR7-]: Change at Week 4 | 7.6 ± 82.42 |
| EM CD8+ T-cell [CD45RA-CCR7-]: Change at Week 8 | -22.8 ± 88.05 |
| EM CD8+ T-cell [CD45RA-CCR7-]: Change at Week 12 | -41.0 ± 85.82 |
| EM CD8+ T-cell [CD45RA-CCR7-]: Change at Week 24 | -69.9 ± 90.17 |
| EM CD8+ T-cell [CD45RA-CCR7-]: Change at Week 36 | -80.3 ± 96.19 |
| EM CD8+ T-cell [CD45RA-CCR7-]: Change at Week 48 | -90.3 ± 97.07 |
| Effector Regulatory T-cells: Baseline | 56.1 ± 28.88 |
| Effector Regulatory T-cells: Change at Week 4 | 0.6 ± 26.13 |
| Effector Regulatory T-cells: Change at Week 8 | -7.1 ± 27.32 |
| Effector Regulatory T-cells: Change at Week 12 | -12.7 ± 25.81 |
| Effector Regulatory T-cells: Change at Week 24 | -20.3 ± 28.31 |
| Effector Regulatory T-cells: Change at Week 36 | -25.8 ± 31.50 |
| Effector Regulatory T-cells: Change at Week 48 | -25.1 ± 29.73 |
| Memory CD4+ T-cell [CD45RA-]: Baseline | 617.7 ± 256.07 |
| Memory CD4+ T-cell [CD45RA-]: Change at Week 4 | -6.2 ± 233.54 |
| Memory CD4+ T-cell [CD45RA-]: Change at Week 8 | -100.9 ± 252.99 |
| Memory CD4+ T-cell [CD45RA-]: Change at Week 12 | -157.7 ± 269.36 |
| Memory CD4+ T-cell [CD45RA-]: Change at Week 24 | -287.7 ± 291.97 |
| Memory CD4+ T-cell [CD45RA-]: Change at Week 36 | -335.0 ± 299.23 |
| Memory CD4+ T-cell [CD45RA-]: Change at Week 48 | -349.9 ± 289.24 |
| Memory CD8+ T-cell [CD45RA-]: Baseline | 187.5 ± 126.58 |
| Memory CD8+ T-cell [CD45RA-]: Change at Week 4 | -4.7 ± 97.59 |
| Memory CD8+ T-cell [CD45RA-]: Change at Week 8 | -40.9 ± 109.49 |
| Memory CD8+ T-cell [CD45RA-]: Change at Week 12 | -64.0 ± 118.89 |
| Memory CD8+ T-cell [CD45RA-]: Change at Week 24 | -108.6 ± 119.94 |
| Memory CD8+ T-cell [CD45RA-]: Change at Week 36 | -124.9 ± 126.30 |
| Memory CD8+ T-cell [CD45RA-]: Change at Week 48 | -136.3 ± 129.68 |
| Naïve CD4+ T-cell [CD45RA+CCR7+]: Baseline | 400.9 ± 261.16 |
| Naïve CD4+ T-cell [CD45RA+CCR7+]: Change at Week 4 | -10.5 ± 175.86 |
| Naïve CD4+ T-cell [CD45RA+CCR7+]: Change at Week 8 | -16.4 ± 169.60 |
| Naïve CD4+ T-cell[CD45RA+CCR7+]:Change at Week 12 | -11.8 ± 177.35 |
| Naïve CD4+ T-cell[CD45RA+CCR7+]:Change at Week 24 | -31.7 ± 190.17 |
| Naïve CD4+ T-cell[CD45RA+CCR7+]:Change at Week 36 | -29.3 ± 204.15 |
| Naïve CD4+ T-cell[CD45RA+CCR7+]:Change at Week 48 | -34.4 ± 197.57 |
| Naïve CD4+ T-cell [CD45RA+]: Baseline | 416.7 ± 268.35 |
| Naïve CD4+ T-cell [CD45RA+]: Change at Week 4 | -8.6 ± 177.59 |
| Naïve CD4+ T-cell [CD45RA+]: Change at Week 8 | -15.6 ± 173.25 |
| Naïve CD4+ T-cell [CD45RA+]: Change at Week 12 | -10.2 ± 185.67 |
| Naïve CD4+ T-cell [CD45RA+]: Change at Week 24 | -33.6 ± 193.78 |
| Naïve CD4+ T-cell [CD45RA+]: Change at Week 36 | -30.2 ± 214.46 |
| Naïve CD4+ T-cell [CD45RA+]: Change at Week 48 | -37.0 ± 206.10 |
| Naïve CD8+ T-cell [CD45RA+CCR7+]: Baseline | 160.1 ± 108.32 |
| Naïve CD8+ T-cell [CD45RA+CCR7+]: Change at Week 4 | -11.6 ± 79.05 |
| Naïve CD8+ T-cell [CD45RA+CCR7+]: Change at Week 8 | -12.4 ± 75.66 |
| Naïve CD8+ T-cell[CD45RA+CCR7+]:Change at Week 12 | -22.0 ± 73.23 |
| Naïve CD8+ T-cell[CD45RA+CCR7+]:Change at Week 24 | -41.3 ± 77.22 |
| Naïve CD8+ T-cell[CD45RA+CCR7+]:Change at Week 36 | -49.0 ± 88.78 |
| Naïve CD8+ T-cell[CD45RA+CCR7+]:Change at Week 48 | -50.9 ± 80.43 |
| Naïve CD8+ T-cell [CD45RA+]: Baseline | 258.0 ± 150.73 |
| Naïve CD8+ T-cell [CD45RA+]: Change at Week 4 | -11.7 ± 118.68 |
| Naïve CD8+ T-cell [CD45RA+]: Change at Week 8 | -28.3 ± 118.33 |
| Naïve CD8+ T-cell [CD45RA+]: Change at Week 12 | -39.7 ± 131.27 |
| Naïve CD8+ T-cell [CD45RA+]: Change at Week 24 | -82.4 ± 134.00 |
| Naïve CD8+ T-cell [CD45RA+]: Change at Week 36 | -106.1 ± 139.47 |
| Naïve CD8+ T-cell [CD45RA+]: Change at Week 48 | -103.4 ± 138.84 |
| Naïve Regulatory T-cells: Baseline | 15.8 ± 13.44 |
| Naïve Regulatory T-cells: Change at Week 4 | -0.1 ± 11.90 |
| Naïve Regulatory T-cells: Change at Week 8 | -0.4 ± 12.19 |
| Naïve Regulatory T-cells: Change at Week 12 | -0.7 ± 9.84 |
| Naïve Regulatory T-cells: Change at Week 24 | -0.4 ± 11.87 |
| Naïve Regulatory T-cells: Change at Week 36 | 0.1 ± 12.07 |
| Naïve Regulatory T-cells: Change at Week 48 | -0.1 ± 10.25 |
| Regulatory T-cells: Baseline | 71.5 ± 36.60 |
| Regulatory T-cells: Change at Week 4 | 1.0 ± 34.31 |
| Regulatory T-cells: Change at Week 8 | -7.3 ± 35.01 |
| Regulatory T-cells: Change at Week 12 | -13.3 ± 32.12 |
| Regulatory T-cells: Change at Week 24 | -20.0 ± 36.77 |
| Regulatory T-cells: Change at Week 36 | -25.7 ± 40.18 |
| Regulatory T-cells: Change at Week 48 | -24.4 ± 36.09 |
| Terminal Effector Regulatory T-cells: Baseline | 327.2 ± 168.48 |
| Terminal Effector Regulatory T-cells: CW 4 | 16.6 ± 158.45 |
| Terminal Effector Regulatory T-cells: CW 8 | -4.4 ± 167.36 |
| Terminal Effector Regulatory T-cells: CW 12 | -17.6 ± 167.80 |
| Terminal Effector Regulatory T-cells: CW 24 | -58.3 ± 174.97 |
| Terminal Effector Regulatory T-cells: CW 36 | -97.2 ± 199.08 |
| Terminal Effector Regulatory T-cells: CW 48 | -98.6 ± 186.01 |
| Th1 phenotype: Baseline | 329.5 ± 153.17 |
| Th1 phenotype: Change at Week 4 | -14.7 ± 127.21 |
| Th1 phenotype: Change at Week 8 | -65.4 ± 147.25 |
| Th1 phenotype: Change at Week 12 | -102.1 ± 149.63 |
| Th1 phenotype: Change at Week 24 | -159.2 ± 172.24 |
| Th1 phenotype: Change at Week 36 | -183.0 ± 177.40 |
| Th1 phenotype: Change at Week 48 | -187.4 ± 172.19 |
| Th17 phenotype: Baseline | 61.9 ± 40.76 |
| Th17 phenotype: Change at Week 4 | -0.5 ± 37.46 |
| Th17 phenotype: Change at Week 8 | -7.3 ± 39.10 |
| Th17 phenotype: Change at Week 12 | -1.1 ± 45.74 |
| Th17 phenotype: Change at Week 24 | -24.6 ± 42.79 |
| Th17 phenotype: Change at Week 36 | -35.1 ± 39.56 |
| Th17 phenotype: Change at Week 48 | -30.1 ± 39.12 |
| Th2-enriched phenotype: Baseline | 562.7 ± 289.42 |
| Th2-enriched phenotype: Change at Week 4 | -0.6 ± 211.18 |
| Th2-enriched phenotype: Change at Week 8 | -31.5 ± 227.69 |
| Th2-enriched phenotype: Change at Week 12 | -54.0 ± 210.95 |
| Th2-enriched phenotype: Change at Week 24 | -96.7 ± 241.83 |
| Th2-enriched phenotype: Change at Week 36 | -97.7 ± 267.45 |
| Th2-enriched phenotype: Change at Week 48 | -125.2 ± 242.46 |
B-cell subsets include CD10+ Transitional B cells, CD138+ Plasma Cells, Ig (Immunoglobulin) D+ Memory B cells \[non-class switched\], IgD- Memory B cells \[class switched\], Naïve B cells, Plasma Cells \[CD10-\], Transitional B-cells and Plasmablasts. Here, Change at week is represented as CW.
| cells/mm^3 | Dimethyl Fumarate (BG00012) |
|---|---|
| CD10+ Transitional B cells: Baseline | 9.4 ± 9.93 |
| CD10+ Transitional B cells: Change at Week 4 | -1.2 ± 7.98 |
| CD10+ Transitional B cells: Change at Week 8 | -0.4 ± 8.73 |
| CD10+ Transitional B cells: Change at Week 12 | -0.4 ± 9.09 |
| CD10+ Transitional B cells: Change at Week 24 | 3.6 ± 10.16 |
| CD10+ Transitional B cells: Change at Week 36 | 2.8 ± 9.53 |
| CD10+ Transitional B cells: Change at Week 48 | 5.7 ± 13.53 |
| CD138+ Plasma Cells: Baseline | 0.26 ± 0.289 |
| CD138+ Plasma Cells: Change at Week 4 | -0.02 ± 0.367 |
| CD138+ Plasma Cells: Change at Week 8 | -0.12 ± 0.291 |
| CD138+ Plasma Cells: Change at Week 12 | -0.15 ± 0.288 |
| CD138+ Plasma Cells: Change at Week 24 | -0.21 ± 0.297 |
| CD138+ Plasma Cells: Change at Week 36 | -0.21 ± 0.327 |
| CD138+ Plasma Cells: Change at Week 48 | -0.19 ± 0.318 |
| IgD+ Memory B cells [non-class switched]: Baseline | 37.8 ± 36.96 |
| IgD+ Memory B cells[non-class switched]: CW 4 | -8.9 ± 26.18 |
| IgD+ Memory B cells[non-class switched]: CW 8 | -12.4 ± 29.27 |
| IgD+ Memory B cells[non-class switched]: CW 12 | -12.1 ± 29.13 |
| IgD+ Memory B cells[non-class switched]: CW 24 | -17.6 ± 31.39 |
| IgD+ Memory B cells[non-class switched]: CW 36 | -19.6 ± 31.61 |
| IgD+ Memory B cells [non-class switched]: CW 48 | -13.4 ± 34.89 |
| IgD- Memory B cells [class switched]: Baseline | 50.4 ± 56.97 |
| IgD- Memory B cells [class switched]: CW 4 | -8.7 ± 32.20 |
| IgD- Memory B cells [class switched]: CW 8 | -17.7 ± 44.42 |
| IgD- Memory B cells [class switched]: CW 12 | -23.1 ± 44.76 |
| IgD- Memory B cells [class switched]: CW 24 | -29.5 ± 49.95 |
| IgD- Memory B cells [class switched]: CW 36 | 49.95 ± 32.64 |
| IgD- Memory B cells [class switched]: CW 48 | -27.4 ± 38.33 |
| Naïve B cells: Baseline | 197.2 ± 140.48 |
| Naïve B cells: Change at Week 4 | -21.5 ± 82.43 |
| Naïve B cells: Change at Week 8 | -37.2 ± 95.32 |
| Naïve B cells: Change at Week 12 | -43.1 ± 99.72 |
| Naïve B cells: Change at Week 24 | -45.7 ± 114.46 |
| Naïve B cells: Change at Week 36 | -54.0 ± 94.94 |
| Naïve B cells: Change at Week 48 | -35.6 ± 107.79 |
| Plasma Cells [CD10-]: Baseline | 0.63 ± 0.668 |
| Plasma Cells [CD10-]: Change at Week 4 | -0.02 ± 0.816 |
| Plasma Cells [CD10-]: Change at Week 8 | -0.11 ± 0.643 |
| Plasma Cells [CD10-]: Change at Week 12 | -0.18 ± 0.647 |
| Plasma Cells [CD10-]: Change at Week 24 | -0.34 ± 0.649 |
| Plasma Cells [CD10-]: Change at Week 36 | -0.33 ± 0.786 |
| Plasma Cells [CD10-]: Change at Week 48 | -0.38 ± 0.633 |
| Transitional B-cells: Baseline | 13.6 ± 13.61 |
| Transitional B-cells: Change at Week 4 | -1.3 ± 11.44 |
| Transitional B-cells: Change at Week 8 | 0.6 ± 12.97 |
| Transitional B-cells: Change at Week 12 | 0.7 ± 13.41 |
| Transitional B-cells: Change at Week 24 | 5.8 ± 15.60 |
| Transitional B-cells: Change at Week 36 | 4.2 ± 13.20 |
| Transitional B-cells: Change at Week 48 | 7.3 ± 18.56 |
| Plasmablasts: Baseline | 0.91 ± 1.104 |
| Plasmablasts: Change at Week 4 | -0.04 ± 1.120 |
| Plasmablasts: Change at Week 8 | -0.21 ± 1.062 |
| Plasmablasts: Change at Week 12 | -0.31 ± 1.024 |
| Plasmablasts: Change at Week 24 | -0.46 ± 1.106 |
| Plasmablasts: Change at Week 36 | -0.46 ± 1.228 |
| Plasmablasts: Change at Week 48 | -0.50 ± 1.084 |
Myeloid and natural killer cell subsets include CD56Bright NK cells, CD56Dim NK cells, Classical Monocytes, Myeloid dendritic cells, Non-classical Monocytes, Plasmacytoid dendritic cells, Total dendritic cells and Total monocytes \[CD14+\].
| cells/mm^3 | Dimethyl Fumarate (BG00012) |
|---|---|
| CD56Bright NK cells: Baseline | 14.0 ± 8.94 |
| CD56Bright NK cells: Change at Week 4 | 1.8 ± 6.40 |
| CD56Bright NK cells: Change at Week 8 | 1.8 ± 7.07 |
| CD56Bright NK cells: Change at Week 12 | 1.3 ± 7.26 |
| CD56Bright NK cells: Change at Week 24 | 2.1 ± 8.57 |
| CD56Bright NK cells: Change at Week 36 | 2.3 ± 9.73 |
| CD56Bright NK cells: Change at Week 48 | 2.1 ± 8.55 |
| CD56Dim NK cells: Baseline | 192.9 ± 130.45 |
| CD56Dim NK cells: Change at Week 4 | -2.0 ± 102.59 |
| CD56Dim NK cells: Change at Week 8 | -17.2 ± 102.92 |
| CD56Dim NK cells: Change at Week 12 | -31.4 ± 92.14 |
| CD56Dim NK cells: Change at Week 24 | -50.7 ± 101.34 |
| CD56Dim NK cells: Change at Week 36 | -61.1 ± 102.96 |
| CD56Dim NK cells: Change at Week 48 | -68.5 ± 129.83 |
| Classical Monocytes: Baseline | 301.4 ± 153.48 |
| Classical Monocytes: Change at Week 4 | 7.5 ± 182.11 |
| Classical Monocytes: Change at Week 8 | 6.0 ± 165.07 |
| Classical Monocytes: Change at Week 12 | 9.3 ± 197.84 |
| Classical Monocytes: Change at Week 24 | -8.7 ± 151.23 |
| Classical Monocytes: Change at Week 36 | -1.5 ± 163.62 |
| Classical Monocytes: Change at Week 48 | -0.8 ± 153.24 |
| Myeloid dendritic cells: Baseline | 24.96 ± 16.315 |
| Myeloid dendritic cells: Change at Week 4 | 1.46 ± 18.111 |
| Myeloid dendritic cells: Change at Week 8 | -0.61 ± 17.670 |
| Myeloid dendritic cells: Change at Week 12 | -0.23 ± 17.932 |
| Myeloid dendritic cells: Change at Week 24 | 3.02 ± 17.882 |
| Myeloid dendritic cells: Change at Week 36 | 3.63 ± 18.779 |
| Myeloid dendritic cells: Change at Week 48 | -6.20 ± 17.780 |
| Non-classical Monocytes: Baseline | 32.0 ± 22.88 |
| Non-classical Monocytes: Change at Week 4 | 2.2 ± 29.82 |
| Non-classical Monocytes: Change at Week 8 | -1.9 ± 30.14 |
| Non-classical Monocytes: Change at Week 12 | -10.8 ± 23.82 |
| Non-classical Monocytes: Change at Week 24 | -6.9 ± 27.65 |
| Non-classical Monocytes: Change at Week 36 | -10.6 ± 24.24 |
| Non-classical Monocytes: Change at Week 48 | -9.2 ± 24.37 |
| Plasmacytoid dendritic cells: Baseline | 6.52 ± 4.617 |
| Plasmacytoid dendritic cells: Change at Week 4 | 0.00 ± 5.168 |
| Plasmacytoid dendritic cells: Change at Week 8 | 0.30 ± 6.427 |
| Plasmacytoid dendritic cells: Change at Week 12 | -0.86 ± 4.575 |
| Plasmacytoid dendritic cells: Change at Week 24 | -0.69 ± 4.138 |
| Plasmacytoid dendritic cells: Change at Week 36 | -0.80 ± 4.086 |
| Plasmacytoid dendritic cells: Change at Week 48 | -2.22 ± 4.509 |
| Total dendritic cells: Baseline | 35.4 ± 19.92 |
| Total dendritic cells: Change at Week 4 | 2.0 ± 22.35 |
| Total dendritic cells: Change at Week 8 | -1.3 ± 21.68 |
| Total dendritic cells: Change at Week 12 | -1.9 ± 21.07 |
| Total dendritic cells: Change at Week 24 | 1.6 ± 21.89 |
| Total dendritic cells: Change at Week 36 | 2.5 ± 22.19 |
| Total dendritic cells: Change at Week 48 | -9.1 ± 22.77 |
| Total monocytes [CD14+]: Baseline | 374.6 ± 179.05 |
| Total monocytes [CD14+]: Change at Week 4 | 26.9 ± 201.63 |
| Total monocytes [CD14+]: Change at Week 8 | 12.6 ± 189.91 |
| Total monocytes [CD14+]: Change at Week 12 | 14.4 ± 211.67 |
| Total monocytes [CD14+]: Change at Week 24 | -19.3 ± 174.82 |
| Total monocytes [CD14+]: Change at Week 36 | -21.7 ± 186.41 |
| Total monocytes [CD14+]: Change at Week 48 | -19.2 ± 175.10 |
T-cell cytokine subsets include IFN (interferon) g+ (% of CD4+ T cells), IFNg+ (% of CD8+ T cells), IFNg+ (% of memory CD4+ T cells), IFNg+ (% of memory CD8+ T cells), IL- (interleukin) 17A+/IFNg- (% of CD4+ T cells), IL-17A+/IFNg- (% of CD8+ T cells), IL-17A+/IFNg- (% of memory CD4+ T cells), IL-17A+/IFNg- (% of memory CD8+ T cells), IL-2+ (% of CD4+ T cells), IL-2+ (% of CD8+ T cells), IL-2+ (% of memory CD4+ T cells), IL-2+ (% of memory CD8+ T cells), IL-4+ (% of CD4+ T cells), IL-4+ (% of CD8+ T cells), IL-4+ (% of memory CD4+ T cells) and IL-4+ (% of memory CD8+ T cells). Here, Change at week is represented as CW.
| cells/mm^3 | Dimethyl Fumarate (BG00012) |
|---|---|
| IFNg+ (% of CD4+ T cells): Baseline | 3.340 ± 2.7365 |
| IFNg+ (% of CD4+ T cells): Change at Week 4 | 0.090 ± 2.2350 |
| IFNg+ (% of CD4+ T cells): Change at Week 8 | -0.356 ± 1.9676 |
| IFNg+ (% of CD4+ T cells): Change at Week12 | -0.729 ± 2.1570 |
| IFNg+ (% of CD4+ T cells): Change at Week24 | -1.134 ± 2.4239 |
| IFNg+ (% of CD4+ T cells): Change at Week36 | -1.511 ± 2.5109 |
| IFNg+ (% of CD4+ T cells): Change at Week48 | -1.222 ± 2.3513 |
| IFNg+ (% of CD8+ T cells): Baseline | 6.166 ± 4.6199 |
| IFNg+ (% of CD8+ T cells): Change at Week 4 | 0.493 ± 2.8636 |
| IFNg+ (% of CD8+ T cells): Change at Week 8 | -0.264 ± 3.0735 |
| IFNg+ (% of CD8+ T cells): Change at Week12 | -1.345 ± 3.3647 |
| IFNg+ (% of CD8+ T cells): Change at Week24 | -1.650 ± 2.7202 |
| IFNg+ (% of CD8+ T cells): Change at Week36 | -1.922 ± 4.1425 |
| IFNg+ (% of CD8+ T cells): Change at Week48 | -1.306 ± 4.3931 |
| IFNg+ (% of memory CD4+ T cells): Baseline | 4.518 ± 3.0417 |
| IFNg+ (% of memory CD4+ T cells): CW 4 | 0.050 ± 2.5996 |
| IFNg+ (% of memory CD4+ T cells): CW 8 | -0.295 ± 2.6287 |
| IFNg+ (% of memory CD4+ T cells): CW 12 | -0.851 ± 2.8590 |
| IFNg+ (% of memory CD4+ T cells): CW 24 | -1.019 ± 2.8120 |
| IFNg+ (% of memory CD4+ T cells): CW 36 | -1.804 ± 2.6448 |
| IFNg+ (% of memory CD4+ T cells): CW 48 | -1.369 ± 3.0958 |
| IFNg+ (% of memory CD8+ T cells): Baseline | 8.795 ± 5.9060 |
| IFNg+ (% of memory CD8+ T cells): CW 4 | 0.360 ± 3.6006 |
| IFNg+ (% of memory CD8+ T cells): CW 8 | -0.285 ± 4.2645 |
| IFNg+ (% of memory CD8+ T cells): CW 12 | -1.543 ± 3.7393 |
| IFNg+ (% of memory CD8+ T cells): CW 24 | -0.964 ± 3.6799 |
| IFNg+ (% of memory CD8+ T cells): CW 36 | -2.035 ± 5.3349 |
| IFNg+ (% of memory CD8+ T cells): CW 48 | -0.497 ± 5.3126 |
| IL-17A+/IFNg- (% of CD4+ T cells): Baseline | 1.244 ± 1.5863 |
| IL-17A+/IFNg- (% of CD4+ T cells):Change at Week4 | 0.115 ± 1.9918 |
| IL-17A+/IFNg- (% of CD4+ T cells):Change at Week8 | 0.131 ± 1.9097 |
| IL-17A+/IFNg- (% of CD4+ T cells):Change at Week12 | 0.470 ± 2.3445 |
| IL-17A+/IFNg- (% of CD4+ T cells):Change at Week24 | 0.165 ± 2.0104 |
| IL-17A+/IFNg- (% of CD4+ T cells):Change at Week36 | 0.419 ± 2.5007 |
| IL-17A+/IFNg- (% of CD4+ T cells):Change at Week48 | 1.693 ± 4.2412 |
| IL-17A+/IFNg- (% of CD8+ T cells): Baseline | 0.455 ± 0.5309 |
| IL-17A+/IFNg- (% of CD8+ T cells):Change at Week4 | 0.239 ± 1.3557 |
| IL-17A+/IFNg- (% of CD8+ T cells):Change at Week8 | 0.032 ± 0.6448 |
| IL-17A+/IFNg- (% of CD8+ T cells):Change at Week12 | 0.301 ± 0.8912 |
| IL-17A+/IFNg- (% of CD8+ T cells):Change at Week24 | 0.289 ± 0.8526 |
| IL-17A+/IFNg- (% of CD8+ T cells):Change at Week36 | 0.911 ± 1.3499 |
| IL-17A+/IFNg- (% of CD8+ T cells):Change at Week48 | 1.457 ± 2.1499 |
| IL-17A+/IFNg- (% of memory CD4+ T cells): Baseline | 1.075 ± 1.1770 |
| IL-17A+/IFNg- (% of memory CD4+T cells): CW 4 | 0.000 ± 1.3599 |
| IL-17A+/IFNg- (% of memory CD4+T cells): CW 8 | 0.040 ± 1.3593 |
| IL-17A+/IFNg- (% of memory CD4+T cells): CW 12 | 0.373 ± 1.7166 |
| IL-17A+/IFNg- (% of memory CD4+T cells): CW 24 | 0.228 ± 1.4980 |
| IL-17A+/IFNg- (% of memory CD4+T cells): CW 36 | 0.333 ± 1.8786 |
| IL-17A+/IFNg- (% of memory CD4+T cells): CW 48 | 1.255 ± 2.9557 |
| IL-17A+/IFNg- (% of memory CD8+ T cells): Baseline | 0.155 ± 0.2356 |
| IL-17A+/IFNg- (% of memory CD8+T cells): CW 4 | 0.113 ± 0.6972 |
| IL-17A+/IFNg- (% of memory CD8+T cells): CW 8 | 0.027 ± 0.3641 |
| IL-17A+/IFNg- (% of memory CD8+T cells): CW 12 | 0.064 ± 0.3641 |
| IL-17A+/IFNg- (% of memory CD8+T cells): CW 24 | 0.254 ± 0.8682 |
| IL-17A+/IFNg- (% of memory CD8+T cells): CW 36 | 0.270 ± 0.6113 |
| IL-17A+/IFNg- (% of memory CD8+T cells): CW 48 | 0.680 ± 1.2842 |
| IL-2+ (% of CD4+ T cells): Baseline | 5.177 ± 4.5225 |
| IL-2+ (% of CD4+ T cells): Change at Week 4 | 0.062 ± 3.4662 |
| IL-2+ (% of CD4+ T cells): Change at Week 8 | 0.149 ± 4.0713 |
| IL-2+ (% of CD4+ T cells): Change at Week 12 | -0.069 ± 4.0822 |
| IL-2+ (% of CD4+ T cells): Change at Week 24 | -0.448 ± 3.6280 |
| IL-2+ (% of CD4+ T cells): Change at Week 36 | -1.837 ± 3.8603 |
| IL-2+ (% of CD4+ T cells): Change at Week 48 | -1.840 ± 5.0951 |
| IL-2+ (% of CD8+ T cells): Baseline | 1.180 ± 1.4533 |
| IL-2+ (% of CD8+ T cells): Change at Week 4 | -0.081 ± 1.2797 |
| IL-2+ (% of CD8+ T cells): Change at Week 8 | -0.227 ± 1.1579 |
| IL-2+ (% of CD8+ T cells): Change at Week 12 | -0.2622 ± 1.2601 |
| IL-2+ (% of CD8+ T cells): Change at Week 24 | -0.525 ± 1.0201 |
| IL-2+ (% of CD8+ T cells): Change at Week 36 | -0.547 ± 1.2886 |
| IL-2+ (% of CD8+ T cells): Change at Week 48 | -0.248 ± 1.1860 |
| IL-2+ (% of memory CD4+ T cells): Baseline | 7.053 ± 5.6653 |
| IL-2+ (% of memory CD4+ T cells): Change at Week 4 | -0.105 ± 4.4131 |
| IL-2+ (% of memory CD4+ T cells): Change at Week 8 | 0.056 ± 4.6541 |
| IL-2+ (% of memory CD4+ T cells): Change at Week12 | 0.012 ± 4.9241 |
| IL-2+ (% of memory CD4+ T cells): Change at Week24 | 0.015 ± 4.6456 |
| IL-2+ (% of memory CD4+ T cells): Change at Week36 | -2.140 ± 4.7723 |
| IL-2+ (% of memory CD4+ T cells): Change at Week48 | -1.946 ± 5.6985 |
| IL-2+ (% of memory CD8+ T cells): Baseline | 1.879 ± 1.7964 |
| IL-2+ (% of memory CD8+ T cells): Change at Week 4 | -0.218 ± 1.6838 |
| IL-2+ (% of memory CD8+ T cells): Change at Week 8 | -0.318 ± 1.7272 |
| IL-2+ (% of memory CD8+ T cells): Change at Week12 | -0.115 ± 1.7354 |
| IL-2+ (% of memory CD8+ T cells): Change at Week24 | -0.461 ± 1.4512 |
| IL-2+ (% of memory CD8+ T cells): Change at Week36 | -0.803 ± 1.8525 |
| IL-2+ (% of memory CD8+ T cells): Change at Week48 | -0.315 ± 2.0510 |
| IL-4+ (% of CD4+ T cells: Baseline | 1.261 ± 1.1190 |
| IL-4+ (% of CD4+ T cells): Change at Week 4 | -0.150 ± 1.0429 |
| IL-4+ (% of CD4+ T cells): Change at Week 8 | -0.113 ± 1.2168 |
| IL-4+ (% of CD4+ T cells): Change at Week12 | -0.370 ± 1.0594 |
| IL-4+ (% of CD4+ T cells): Change at Week24 | -0.170 ± 1.1551 |
| IL-4+ (% of CD4+ T cells): Change at Week36 | -0.376 ± 1.0920 |
| IL-4+ (% of CD4+ T cells): Change at Week48 | 0.281 ± 4.7206 |
| IL-4+ (% of CD8+ T cells): Baseline | 1.107 ± 1.2924 |
| IL-4+ (% of CD8+ T cells): Change at Week 4 | -0.222 ± 1.2163 |
| IL-4+ (% of CD8+ T cells): Change at Week 8 | -0.189 ± 1.3377 |
| IL-4+ (% of CD8+ T cells): Change at Week12 | -0.553 ± 1.3754 |
| IL-4+ (% of CD8+ T cells): Change at Week24 | -0.032 ± 1.3170 |
| IL-4+ (% of CD8+ T cells): Change at Week36 | -0.195 ± 1.3334 |
| IL-4+ (% of CD8+ T cells): Change at Week48 | 0.786 ± 1.3454 |
| IL-4+ (% of memory CD4+ T cells): Baseline | 1.406 ± 1.2437 |
| IL-4+ (% of memory CD4+ T cells): Change at Week 4 | -0.128 ± 1.2649 |
| IL-4+ (% of memory CD4+ T cells): Change at Week 8 | -0.141 ± 1.4642 |
| IL-4+ (% of memory CD4+ T cells): Change at Week12 | -0.412 ± 1.3656 |
| IL-4+ (% of memory CD4+ T cells): Change at Week24 | -0.136 ± 1.3059 |
| IL-4+ (% of memory CD4+ T cells): Change at Week36 | -0.266 ± 1.4005 |
| IL-4+ (% of memory CD4+ T cells): Change at Week48 | 0.325 ± 1.7918 |
| IL-4+ (% of memory CD8+ T cells): Baseline | 1.376 ± 1.8963 |
| IL-4+ (% of memory CD8+ T cells): Change at Week 4 | -0.180 ± 2.0821 |
| IL-4+ (% of memory CD8+ T cells): Change at Week 8 | -0.269 ± 1.9840 |
| IL-4+ (% of memory CD8+ T cells): Change at Week12 | -0.795 ± 2.2486 |
| IL-4+ (% of memory CD8+ T cells): Change at Week24 | 0.416 ± 2.3613 |
| IL-4+ (% of memory CD8+ T cells): Change at Week36 | -0.284 ± 2.4433 |
| IL-4+ (% of memory CD8+ T cells): Change at Week48 | 1.836 ± 2.7709 |
VLA-4/LFA-1 antigen subsets include CD11a+ (% of B cells), CD11a+ (% of T cells), CD11a+ (% of MNC), CD11a+ (% of dendritic cells \[CD11c++\]), CD11a+ (% of lymphocytes), CD11a+ (% of monocytes), CD11a+ (% of neutrophils), CD49d+ (% of B cells), CD49d+ (% of T cells), CD49d+ (% of MNC), CD49d+ (% of dendritic cells \[CD11c++\]), CD49d+ (% of lymphocytes), CD49d+ (% of monocytes) and CD49d+ (% of neutrophils).
| cells/mm^3 | Dimethyl Fumarate (BG00012) |
|---|---|
| CD11a+ (% of B cells): Baseline | 99.33 ± 2.106 |
| CD11a+ (% of B cells): Change at Week 4 | 0.34 ± 2.497 |
| CD11a+ (% of B cells): Change at Week 8 | 0.44 ± 2.203 |
| CD11a+ (% of B cells): Change at Week 12 | 0.17 ± 2.534 |
| CD11a+ (% of B cells): Change at Week 24 | 0.19 ± 2.549 |
| CD11a+ (% of B cells): Change at Week 36 | -1.43 ± 11.406 |
| CD11a+ (% of B cells): Change at Week 48 | -0.14 ± 7.751 |
| CD11a+ (% of T cells): Baseline | 99.90 ± 0.312 |
| CD11a+ (% of T cells): Change at Week 4 | 0.05 ± 0.319 |
| CD11a+ (% of T cells): Change at Week 8 | 0.07 ± 0.327 |
| CD11a+ (% of T cells): Change at Week 12 | 0.06 ± 0.321 |
| CD11a+ (% of T cells): Change at Week 24 | 0.02 ± 0.633 |
| CD11a+ (% of T cells): Change at Week 36 | -1.29 ± 9.760 |
| CD11a+ (% of T cells): Change at Week 48 | -0.53 ± 7.410 |
| CD11a+ (% of MNC): Baseline | 96.85 ± 3.089 |
| CD11a+ (% of MNC): Change at Week 4 | 0.47 ± 3.630 |
| CD11a+ (% of MNC): Change at Week 8 | 0.59 ± 3.532 |
| CD11a+ (% of MNC): Change at Week 12 | 0.59 ± 3.710 |
| CD11a+ (% of MNC): Change at Week 24 | -0.38 ± 3.963 |
| CD11a+ (% of MNC): Change at Week 36 | -1.55 ± 10.918 |
| CD11a+ (% of MNC): Change at Week 48 | -2.31 ± 8.402 |
| CD11a+ (% of dendritic cells [CD11c++]): Baseline | 99.81 ± 0.933 |
| CD11a+ (% of dendritic cells [CD11c++]): CW 4 | 0.04 ± 0.867 |
| CD11a+ (% of dendritic cells [CD11c++]): CW 8 | 0.02 ± 1.573 |
| CD11a+ (% of dendritic cells [CD11c++]): CW 12 | 0.10 ± 1.250 |
| CD11a+ (% of dendritic cells [CD11c++]): CW 24 | 0.01 ± 1.477 |
| CD11a+ (% of dendritic cells [CD11c++]): CW 36 | -1.27 ± 10.857 |
| CD11a+ (% of dendritic cells [CD11c++]): CW 48 | -0.84 ± 7.813 |
| CD11a+ (% of lymphocytes): Baseline | 98.24 ± 1.870 |
| CD11a+ (% of lymphocytes): Change at Week 4 | 0.04 ± 2.227 |
| CD11a+ (% of lymphocytes): Change at Week 8 | 0.07 ± 2.649 |
| CD11a+ (% of lymphocytes): Change at Week 12 | 0.26 ± 2.604 |
| CD11a+ (% of lymphocytes): Change at Week 24 | -0.35 ± 2.519 |
| CD11a+ (% of lymphocytes): Change at Week 36 | -1.99 ± 10.532 |
| CD11a+ (% of lymphocytes): Change at Week 48 | -2.56 ± 8.696 |
| CD11a+ (% of monocytes): Baseline | 98.00 ± 2.303 |
| CD11a+ (% of monocytes): Change at Week 4 | 0.29 ± 3.241 |
| CD11a+ (% of monocytes): Change at Week 8 | 0.92 ± 2.416 |
| CD11a+ (% of monocytes): Change at Week 12 | 0.77 ± 2.539 |
| CD11a+ (% of monocytes): Change at Week 24 | -0.40 ± 3.046 |
| CD11a+ (% of monocytes): Change at Week 36 | -0.36 ± 7.843 |
| CD11a+ (% of monocytes): Change at Week 48 | -1.52 ± 7.711 |
| CD11a+ (% of neutrophils): Baseline | 97.80 ± 5.352 |
| CD11a+ (% of neutrophils): Change at Week 4 | 0.83 ± 6.672 |
| CD11a+ (% of neutrophils): Change at Week 8 | 1.23 ± 5.675 |
| CD11a+ (% of neutrophils): Change at Week 12 | 0.55 ± 6.113 |
| CD11a+ (% of neutrophils): Change at Week 24 | 0.35 ± 9.220 |
| CD11a+ (% of neutrophils): Change at Week 36 | -2.88 ± 18.513 |
| CD11a+ (% of neutrophils): Change at Week 48 | 0.42 ± 10.736 |
| CD49d+ (% of B cells): Baseline | 99.87 ± 0.679 |
| CD49d+ (% of B cells): Change at Week 4 | -0.50 ± 7.105 |
| CD49d+ (% of B cells): Change at Week 8 | 0.00 ± 0.642 |
| CD49d+ (% of B cells): Change at Week 12 | 0.01 ± 0.486 |
| CD49d+ (% of B cells): Change at Week 24 | -0.01 ± 0.663 |
| CD49d+ (% of B cells): Change at Week 36 | -0.07 ± 0.744 |
| CD49d+ (% of B cells): Change at Week 48 | -0.04 ± 0.964 |
| CD49d+ (% of T cells): Baseline | 91.23 ± 4.427 |
| CD49d+ (% of T cells): Change at Week 4 | -0.45 ± 6.909 |
| CD49d+ (% of T cells): Change at Week 8 | -0.11 ± 2.055 |
| CD49d+ (% of T cells): Change at Week 12 | -0.06 ± 1.930 |
| CD49d+ (% of T cells): Change at Week 24 | -0.12 ± 2.209 |
| CD49d+ (% of T cells): Change at Week 36 | -1.32 ± 4.256 |
| CD49d+ (% of T cells): Change at Week 48 | -0.02 ± 2.935 |
| CD49d+ (% of MNC): Baseline | 86.79 ± 5.369 |
| CD49d+ (% of MNC): Change at Week 4 | 0.23 ± 8.274 |
| CD49d+ (% of MNC): Change at Week 8 | 0.38 ± 5.600 |
| CD49d+ (% of MNC): Change at Week 12 | 0.85 ± 5.900 |
| CD49d+ (% of MNC): Change at Week 24 | -0.07 ± 6.051 |
| CD49d+ (% of MNC): Change at Week 36 | -0.46 ± 8.264 |
| CD49d+ (% of MNC): Change at Week 48 | -1.25 ± 6.561 |
| CD49d+ (% of dendritic cells [CD11c++]): Baseline | 99.77 ± 0.771 |
| CD49d+ (% of dendritic cells [CD11c++]): CW 4 | -0.42 ± 7.185 |
| CD49d+ (% of dendritic cells [CD11c++]): CW 8 | 0.12 ± 0.874 |
| CD49d+ (% of dendritic cells [CD11c++]): CW 12 | 0.03 ± 1.252 |
| CD49d+ (% of dendritic cells [CD11c++]): CW 24 | 0.00 ± 1.162 |
| CD49d+ (% of dendritic cells [CD11c++]): CW 36 | -0.06 ± 1.532 |
| CD49d+ (% of dendritic cells [CD11c++]): CW 48 | -0.23 ± 1.530 |
| CD49d+ (% of lymphocytes): Baseline | 91.29 ± 4.715 |
| CD49d+ (% of lymphocytes): Change at Week 4 | -0.31 ± 7.260 |
| CD49d+ (% of lymphocytes): Change at Week 8 | 0.03 ± 5.899 |
| CD49d+ (% of lymphocytes): Change at Week 12 | 0.44 ± 2.989 |
| CD49d+ (% of lymphocytes): Change at Week 24 | 0.01 ± 3.237 |
| CD49d+ (% of lymphocytes): Change at Week 36 | -0.75 ± 5.045 |
| CD49d+ (% of lymphocytes): Change at Week 48 | -1.10 ± 5.739 |
| CD49d+ (% of monocytes): Baseline | 88.77 ± 8.126 |
| CD49d+ (% of monocytes): Change at Week 4 | 0.82 ± 10.895 |
| CD49d+ (% of monocytes): Change at Week 8 | 0.96 ± 10.161 |
| CD49d+ (% of monocytes): Change at Week 12 | 0.82 ± 10.350 |
| CD49d+ (% of monocytes): Change at Week 24 | 0.98 ± 9.793 |
| CD49d+ (% of monocytes): Change at Week 36 | 3.87 ± 9.683 |
| CD49d+ (% of monocytes): Change at Week 48 | 0.69 ± 10.594 |
| CD49d+ (% of neutrophils): Baseline | 5.61 ± 7.277 |
| CD49d+ (% of neutrophils): Change at Week 4 | 4.43 ± 9.345 |
| CD49d+ (% of neutrophils): Change at Week 8 | 1.17 ± 4.892 |
| CD49d+ (% of neutrophils): Change at Week 12 | 0.27 ± 4.137 |
| CD49d+ (% of neutrophils): Change at Week 24 | -0.67 ± 10.365 |
| CD49d+ (% of neutrophils): Change at Week 36 | -0.29 ± 12.678 |
| CD49d+ (% of neutrophils): Change at Week 48 | 0.92 ± 10.291 |
| milligram per liter (mg/L) | Dimethyl Fumarate (BG00012) |
|---|---|
| Baseline | 2116.5 ± 910.47 |
| Change at Week 4 | -120.0 ± 231.16 |
| Change at Week 8 | -112.8 ± 243.28 |
| Change at Week 12 | -93.6 ± 291.76 |
| Change at Week 24 | -101.5 ± 324.27 |
| Change at Week 36 | -65.1 ± 279.53 |
| Change at Week 48 | -94.9 ± 291.25 |
| mg/L | Dimethyl Fumarate (BG00012) |
|---|---|
| Baseline | 1330.1 ± 705.92 |
| Change at Week 4 | -68.9 ± 214.07 |
| Change at Week 8 | -23.2 ± 208.48 |
| Change at Week 12 | -18.8 ± 270.82 |
| Change at Week 24 | -36.9 ± 293.14 |
| Change at Week 36 | -19.4 ± 406.86 |
| Change at Week 48 | -96.8 ± 236.48 |
| g/L | Dimethyl Fumarate (BG00012) |
|---|---|
| Baseline | 10.51 ± 2.328 |
| Change at Week 4 | -0.77 ± 1.039 |
| Change at Week 8 | -0.64 ± 1.077 |
| Change at Week 12 | -0.44 ± 1.187 |
| Change at Week 24 | -0.62 ± 1.324 |
| Change at Week 36 | -0.36 ± 1.025 |
| Change at Week 48 | -0.53 ± 1.142 |
| milligram per deciliter | Dimethyl Fumarate (BG00012) |
|---|---|
| IgG Subclass 1: Baseline | 542.9 ± 152.87 |
| IgG Subclass 1: Change at Week 4 | -29.2 ± 68.22 |
| IgG Subclass 1: Change at Week 8 | -28.5 ± 71.46 |
| IgG Subclass 1: Change at Week 12 | -14.8 ± 79.07 |
| IgG Subclass 1: Change at Week 24 | -3.0 ± 78.80 |
| IgG Subclass 1: Change at Week 36 | -23.1 ± 61.73 |
| IgG Subclass 1: Change at Week 48 | -0.5 ± 102.41 |
| IgG Subclass 2: Baseline | 350.7 ± 116.43 |
| IgG Subclass 2: Change at Week 4 | -22.7 ± 47.42 |
| IgG Subclass 2: Change at Week 8 | -26.5 ± 48.98 |
| IgG Subclass 2: Change at Week 12 | -18.9 ± 44.11 |
| IgG Subclass 2: Change at Week 24 | -5.5 ± 54.39 |
| IgG Subclass 2: Change at Week 36 | -22.4 ± 45.49 |
| IgG Subclass 2: Change at Week 48 | -21.5 ± 50.98 |
| IgG Subclass 3: Baseline | 56.93 ± 26.860 |
| IgG Subclass 3: Change at Week 4 | -2.1 ± 8.56 |
| IgG Subclass 3: Change at Week 8 | -0.7 ± 12.36 |
| IgG Subclass 3: Change at Week 12 | -1.0 ± 15.48 |
| IgG Subclass 3: Change at Week 24 | -0.4 ± 11.31 |
| IgG Subclass 3: Change at Week 36 | 4.6 ± 19.09 |
| IgG Subclass 3: Change at Week 48 | 1.5 ± 12.55 |
| IgG Subclass 4: Baseline | 30.35 ± 29.681 |
| IgG Subclass 4: Change at Week 4 | 1.24 ± 9.242 |
| IgG Subclass 4: Change at Week 8 | -0.38 ± 10.995 |
| IgG Subclass 4: Change at Week 12 | -0.12 ± 11.711 |
| IgG Subclass 4: Change at Week 24 | 1.08 ± 15.253 |
| IgG Subclass 4: Change at Week 36 | 1.28 ± 12.236 |
| IgG Subclass 4: Change at Week 48 | 3.26 ± 10.962 |
| IgG Subclasses 1-4 Quant: Baseline | 1029.9 ± 232.33 |
| IgG Subclasses 1-4 Quant: Change at Week 4 | -54.6 ± 101.48 |
| IgG Subclasses 1-4 Quant: Change at Week 8 | -41.9 ± 100.16 |
| IgG Subclasses 1-4 Quant: Change at Week 12 | -28.5 ± 114.30 |
| IgG Subclasses 1-4 Quant: Change at Week 24 | -55.7 ± 116.69 |
| IgG Subclasses 1-4 Quant: Change at Week 36 | -70.3 ± 103.59 |
| IgG Subclasses 1-4 Quant: Change at Week 48 | -65.1 ± 130.94 |
Collected over Up to 33 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dimethyl Fumarate (BG00012) | 0/218 (0%) | 26/218 (11.9%) | 160/218 (73.4%) |
| Event | Dimethyl Fumarate (BG00012) |
|---|---|
| Multiple sclerosis relapseNervous system disorders | 16/218 |
| Acute myocardial infarctionCardiac disorders | 1/218 |
| IridocyclitisEye disorders | 1/218 |
| Non-cardiac chest painGeneral disorders | 1/218 |
| Cholecystitis chronicHepatobiliary disorders | 1/218 |
| CellulitisInfections and infestations | 1/218 |
| NasopharyngitisInfections and infestations | 1/218 |
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 1/218 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 1/218 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/218 |
| Event | Dimethyl Fumarate (BG00012) |
|---|---|
| FlushingVascular disorders | 100/218 |
| Multiple sclerosis relapseNervous system disorders | 41/218 |
| NasopharyngitisInfections and infestations | 33/218 |
| DiarrhoeaGastrointestinal disorders | 28/218 |
| Upper respiratory tract infectionInfections and infestations | 28/218 |
| FatigueGeneral disorders | 27/218 |
| Abdominal painGastrointestinal disorders | 22/218 |
| Abdominal pain upperGastrointestinal disorders | 22/218 |
| NauseaGastrointestinal disorders | 22/218 |
| PruritusSkin and subcutaneous tissue disorders | 17/218 |
The pharmacodynamic (PD) population was defined as all participants who received at least 1 dose of study treatment and had at least 1 pharmacodynamic measurement after baseline.
| Age, Continuous(years) | Dimethyl Fumarate (BG00012) |
|---|---|
| Mean | 42.1 ± 10.99 |
| Sex: Female, Male(Participants) | Dimethyl Fumarate (BG00012) |
|---|---|
| Female | 151 |
| Male | 67 |
| Ethnicity (NIH/OMB)(Participants) | Dimethyl Fumarate (BG00012) |
|---|---|
| Hispanic or Latino | 6 |
| Not Hispanic or Latino | 66 |
| Unknown or Not Reported | 146 |
| Race (NIH/OMB)(Participants) | Dimethyl Fumarate (BG00012) |
|---|---|
| American Indian or Alaska Native | 1 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 60 |
| More than one race | 3 |
| Unknown or Not Reported | 145 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2015 to primary completion in Apr 2017, 20 months.
Results were first posted in Jun 2019, 2 years 2 months after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 20 months is below that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dimethyl Fumarate
Multiple Sclerosis, Relapsing-Remitting →